EE333 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the U.S.: An Updated Analysis
Abstract
Authors
D Campbell D Veenstra K. Migliaccio-Walle M Dzingina S Sullivan F Draica T Wiemken A. Cha-Silva T Mugwagwa